Healthcare -
Biotechnology - NASDAQ - US
$ 5.1
-1.16 %
$ 263 M
Market Cap
-1.39
P/E
1. INTRINSIC VALUE
Balance Sheet
Verastem, Inc.
| Current Assets | 95 M |
| Cash & Short-Term Investments | 88.8 M |
| Receivables | 200 K |
| Other Current Assets | 5.94 M |
| Non-Current Assets | 6.58 M |
| Long-Term Investments | 0 |
| PP&E | 1.44 M |
| Other Non-Current Assets | 5.14 M |
| Current Liabilities | 31 M |
| Accounts Payable | 4.03 M |
| Short-Term Debt | 995 K |
| Other Current Liabilities | 26 M |
| Non-Current Liabilities | 99.5 M |
| Long-Term Debt | 41.3 M |
| Other Non-Current Liabilities | 58.2 M |
EFFICIENCY
Earnings Waterfall
Verastem, Inc.
| Revenue | 10 M |
| Cost Of Revenue | 0 |
| Gross Profit | 10 M |
| Operating Expenses | 125 M |
| Operating Income | -115 M |
| Other Expenses | 15.7 M |
| Net Income | -131 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Verastem, Inc.
| Net Income | -131 M |
| Depreciation & Amortization | 26 K |
| Capital Expenditures | -28 K |
| Stock-Based Compensation | 7.34 M |
| Change in Working Capital | 3.72 M |
| Others | 21.7 M |
| Free Cash Flow | -105 M |
Wall Street Analysts Price Targets
Verastem, Inc.
Wall Street analysts predict an average 1-year price target for VSTM of $11 , with forecasts ranging from
a
low of
$7 to a high of $14 .
VSTM Lowest Price Target
Wall Street Target
7 USD
37.25%
VSTM Average Price Target
Wall Street Target
11 USD
115.69%
VSTM Highest Price Target
Wall Street Target
14 USD
174.51%
4. DIVIDEND
ANALYSIS
VSTM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Verastem, Inc.
Sold
0-3 MONTHS
13.3 K USD 4
3-6 MONTHS
56.4 K USD 4
6-9 MONTHS
12.3 K USD 4
9-12 MONTHS
6.31 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of its common stock to fourteen new employees and the grant of 83,333 restricted stock units to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology.
businesswire.com
- 2 weeks ago
Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 3 weeks ago
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 to be held on April 25-30 in Chicago, Illinois. These presentations will highlight clinical and preclinical data from the Company's development programs, including VS-7375 (GFH375), an oral KRAS.
businesswire.com
- 3 weeks ago
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2024, and highlighted recent progress. “In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of avutometinib plus defactinib for Priority Review under the accelerated approval pathway f.
businesswire.com
- 1 month ago
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025, at 1:00 pm EST. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company's website at www.v.
businesswire.com
- 2 months ago
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming catalysts for its novel clinical pipeline. "We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with Priority Review for avutometinib plus defactinib in recurrent KRAS mutant low-grade serous ovarian cancer. As we h.
businesswire.com
- 2 months ago
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. “We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid.
businesswire.com
- 3 months ago
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced a new credit facility for up to $150 million along with an equity investment of $7.5 million with Oberland Capital Management LLC (Oberland Capital). In addition, the Company announced a strategic collaboration with IQVIA Inc. (IQVIA) to leverage IQVIA's world-class infrastructure and established commercial.
businesswire.com
- 3 months ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have.
businesswire.com
- 3 months ago
Verastem: Planning The PDUFA Run-Up
Verastem, Inc.'s NDA for avutometinib and defactinib in recurrent KRAS-mutant LGSOC has been accepted by the FDA, with a PDUFA date set for June 30, 2025. The combination therapy shows promising Phase II RAMP 201 results, with a 31% ORR and significant tumor size reduction, potentially positioning Verastem as a commercial-stage company by 2025. The LGSOC market is projected to reach $363.7M by 2034, with Verastem's therapy poised to capture a significant share due to the lack of approved treatments.
seekingalpha.com
- 3 months ago
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Financially, VSTM has limited cash reserves, with only 4-5 quarters of operating funds, posing a risk if there are approval delays. The market size for their therapy is uncertain, with potential revenues ranging from $85.7 million to $686 million annually.
seekingalpha.com
- 3 months ago
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
zacks.com
- 3 months ago
8. Profile
Summary
Verastem, Inc. VSTM
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 263 M
Dividend Yield
0.00%
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Contact
117 Kendrick Street, Needham, MA, 02494
https://www.verastem.com
IPO
Date
Jan. 27, 2012
Employees
78
Officers
Mr. Michael Crowther
Chief Commercial & Strategy Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Mr. Matthew E. Ros
Chief Operating Officer
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Mr. Daniel Calkins
Chief Financial Officer
Mr. Nate Sanburn
Chief Business Officer
Dr. Michelle Detwiler M.D., Ph.D.
Co-Founder
Ms. Colleen Mockbee
Global Head of Regulatory Affairs & Development
Mr. Daniel W. Paterson
President, Chief Executive Officer & Director